A randomized, double-blind, placebo-controlled, multicenter, crossover study of the safety, efficacy and pharmacokinetics of two escalating, oral doses of V3381 [indantadol] (200 mg bid and 400 mg bid) for 28 days in patients with diabetic peripheral neuropathic pain (DPNP)

Trial Profile

A randomized, double-blind, placebo-controlled, multicenter, crossover study of the safety, efficacy and pharmacokinetics of two escalating, oral doses of V3381 [indantadol] (200 mg bid and 400 mg bid) for 28 days in patients with diabetic peripheral neuropathic pain (DPNP)

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Apr 2007

At a glance

  • Drugs Indantadol (Primary)
  • Indications Diabetic neuropathies; Neuropathic pain
  • Focus Therapeutic Use
  • Sponsors Vernalis
  • Most Recent Events

    • 04 Nov 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top